230 related articles for article (PubMed ID: 7588899)
1. Physiological and pathological responses of TU waves to class Ia antiarrhythmic drugs.
Maruyama T; Ohe T; Kurita T; Aihara N; Shimizu W
Eur Heart J; 1995 May; 16(5):667-73. PubMed ID: 7588899
[TBL] [Abstract][Full Text] [Related]
2. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
Hii JT; Wyse DG; Gillis AM; Duff HJ; Solylo MA; Mitchell LB
Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
[TBL] [Abstract][Full Text] [Related]
3. Differences in corrected QT intervals at minimal and maximal heart rate may identify patients at risk for torsades de pointes during treatment with antiarrhythmic drugs.
Buckingham TA; Bhutto ZR; Telfer EA; Zbilut J
J Cardiovasc Electrophysiol; 1994 May; 5(5):408-11. PubMed ID: 8055145
[TBL] [Abstract][Full Text] [Related]
4. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
[TBL] [Abstract][Full Text] [Related]
5. Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms.
Morganroth J
Am J Cardiol; 1993 Aug; 72(6):10B-13B. PubMed ID: 8256748
[TBL] [Abstract][Full Text] [Related]
6. Early afterdepolarizationlike activity in patients with class IA induced long QT syndrome and torsades de pointes.
Kurita T; Ohe T; Shimizu W; Suyama K; Aihara N; Takaki H; Kamakura S; Shimomura K
Pacing Clin Electrophysiol; 1997 Mar; 20(3 Pt 1):695-705. PubMed ID: 9080496
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
Kühlkamp V; Mermi J; Mewis C; Seipel L
J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
[TBL] [Abstract][Full Text] [Related]
8. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome.
Johansson M; Carlsson L
J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):247-54. PubMed ID: 11584331
[TBL] [Abstract][Full Text] [Related]
9. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
Oberg KC; Bauman JL
Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
[TBL] [Abstract][Full Text] [Related]
10. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes.
Antzelevitch C
Heart Rhythm; 2005 Nov; 2(2 Suppl):S9-15. PubMed ID: 16253930
[TBL] [Abstract][Full Text] [Related]
11. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study.
Houltz B; Darpö B; Edvardsson N; Blomström P; Brachmann J; Crijns HJ; Jensen SM; Svernhage E; Vallin H; Swedberg K
Pacing Clin Electrophysiol; 1998 May; 21(5):1044-57. PubMed ID: 9604236
[TBL] [Abstract][Full Text] [Related]
12. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
Skanes AC; Morton BC; Green MS; Tang AS
Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
[TBL] [Abstract][Full Text] [Related]
13. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
[TBL] [Abstract][Full Text] [Related]
14. Torsades de pointes associated with acquired long QT syndrome: observation of 7 cases.
Takahashi N; Ito M; Inoue T; Koumatsu K; Takeshita Y; Tsumabuki S; Tamura M; Inoue K; Maeda T; Saikawa T
J Cardiol; 1993; 23(1):99-106. PubMed ID: 8164140
[TBL] [Abstract][Full Text] [Related]
15. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.
Tisdale JE; Rasty S; Padhi ID; Sharma ND; Rosman H
J Clin Pharmacol; 2001 Dec; 41(12):1310-8. PubMed ID: 11762558
[TBL] [Abstract][Full Text] [Related]
16. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
17. Measuring the risk of torsades de pointes: electrocardiographic evaluation of PNU-142093 in conscious cynomolgus non-human primates using restraint and non-restraint procedures.
Bass AS; Hanson LA; Jackson TA
J Pharmacol Toxicol Methods; 2009; 60(1):51-7. PubMed ID: 19447184
[TBL] [Abstract][Full Text] [Related]
18. Current status of class III antiarrhythmic drug therapy.
Roden DM
Am J Cardiol; 1993 Aug; 72(6):44B-49B. PubMed ID: 8256755
[TBL] [Abstract][Full Text] [Related]
19. Global electrical heterogeneity associated with drug-induced torsades de pointes.
Stabenau HF; Shen C; Zimetbaum P; Buxton AE; Tereshchenko LG; Waks JW
Heart Rhythm; 2021 Jan; 18(1):57-62. PubMed ID: 32781158
[TBL] [Abstract][Full Text] [Related]
20. Flecainide induced ventricular tachycardia (torsades de pointes).
Thevenin J; Da Costa A; Roche F; Romeyer C; Messier M; Isaaz K
Pacing Clin Electrophysiol; 2003 Sep; 26(9):1907-8. PubMed ID: 12930510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
